Matrix buys back marketing rights for AccuSite:
This article was originally published in Clinica
Matrix Pharmaceutical has repurchased US and European marketing rights to its AccuSite injectable gel product from Medeva (UK). The company intends to establish a direct sales organisation to market AccuSite and Intradose in the US. In August, Matrix filed for approval in the UK for AccuSite and it plans to submit its New Drug Application with the US FDA for the treatment of genital warts later this month.